Altre lingue N4 Pharma Plc

Azioni

Mercato chiuso - London S.E. Altri mercati azionari 17:35:21 10/05/2024			Variaz. 5gg	Var. 1 gen.
0,8 ^GBX	0,00%		0,00%	-5,88%

25/04	N4 Pharma stringe un accordo di collaborazione per la somministrazione intracellulare	AN
23/04	La perdita di N4 Pharma aumenta, ma rimane un "grande ottimismo".	AN

N4 Pharma strikes partnership deal for intracellular delivery	25/04
N4 Pharma loss widens but "great optimism" remains	23/04
N4 Pharma Plc Reports Earnings Results for the Full Year Ended December 31, 2023	23/04
N4 Pharma sees potential in Nuvec delivery method for cancer treatment	18/04
N4 Pharma’s In Vivo Testing Shows Nuvec’s Potential as Oral Delivery System	18/04
Police Arrest Two Over Attempt to Kill Murder Case	16/04
N4 Pharma's In-vitro Study Shows Nuvec's Versatility in Inhibiting Cancer Cells	15/02
N4 Pharma shares rise on "encouraging" Nuvec research	15/02
AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets	15/02
N4 Pharma plc Provides In-Vitro siRNA Update	15/02
N4 Pharma's Nuvec Granted Patent in India	19/01
N4 Pharma gets India patent for medical delivery system	19/01
N4 Pharma touts contract to test glaucoma treatment, ECP105	16/01
N4 Pharma Unit to Prepare Glaucoma Treatment Candidate for Pre-clinical Trials; Shares Plunge	16/01
N4 Pharma Shows Increased Transduction Efficacy for Silica Nanoparticle	08/01
N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8	08/01
N4 Pharma plc Provides A Further Successful Update on Its Ongoing Research Work into the Use of Nuvec to Enhance the Performance of Viral Vector	08/01
FTSE 100 outperforms European peers	18/12
N4 Pharma rises on successful results from Nuvec administration	18/12
N4 Pharma Plc Provides Positive Update on its Ongoing Oral Delivery Research Work	18/12

Non ci sono risultati per questa ricerca